Oxidant /Antioxidant Status in Newly Diagnosed Patients with Parkinsonism :Effects of Therapy

Abstract

To assess effects of a fixed therapy on the oxidant (malondialdehyde ''MDA'' levels)/ antioxidant status (Total antioxidant status "TAS")in newly diagnosed patients with Parkinson disease in comparison to healthy controls. Thirty eight newly diagnosed patients with Parkinson disease were included in this study. they were referred cases from neurologist Clinic from October 2009 to February 2011. included also in the study 40 apparently healthy age and sex matched subjects as a control groups. A blood samples were taken initially from the patients before starting therapy and the controls and assay of serum MDA and TAS were done. Body mass index (BMI) were calculated according to a certain equation. Patients then were put on fixed therapy for 3 months after which another blood samples were taken and assay of the same parameters were done. There was a significantly elevated serum MDA and a significantly lowered serum TAS levels in newly diagnosed patients with Parkinson disease in comparison to healthy controls. After therapy patients still having a highly significant difference in the levels of serum MDA and TAS in comparison to controls. There was insignificant difference in the serum levels of MDA and TAS between patients in the pre-therapy and post-therapy stages. Newly diagnosed patients with Parkinson disease having signs of oxidation stress, and that the specific anti parkinsonian therapy used in this study have no significant effect on the shifted oxidant/ antioxidant status.